Waterstone Capital Management LP Boosted Its Hologic (HOLX) Stake; Ovascience (OVAS) Sentiment Is 0.66

October 13, 2017 - By Migdalia James

OvaScience, Inc. is a global fertility company. The company has market cap of $52.10 million. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. It currently has negative earnings. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor cells from a patient’s own ovarian tissue.

Waterstone Capital Management Lp increased Hologic Inc (HOLX) stake by 11.98% reported in 2017Q2 SEC filing. Waterstone Capital Management Lp acquired 45,000 shares as Hologic Inc (HOLX)’s stock rose 7.50%. The Waterstone Capital Management Lp holds 420,500 shares with $19.08 million value, up from 375,500 last quarter. Hologic Inc now has $10.19 billion valuation. The stock declined 0.63% or $0.23 reaching $36.33 on the news. About 1.66M shares traded. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since October 13, 2016 and is uptrending. It has outperformed by 12.51% the S&P500.

Among 17 analysts covering Hologic (NASDAQ:HOLX), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Hologic had 40 analyst reports since July 24, 2015 according to SRatingsIntel. Needham maintained Hologic, Inc. (NASDAQ:HOLX) rating on Wednesday, August 23. Needham has “Buy” rating and $50.0 target. Needham maintained it with “Buy” rating and $5000 target in Friday, June 2 report. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Buy” rating given on Thursday, January 28 by Needham. The rating was maintained by Needham on Wednesday, July 5 with “Buy”. On Friday, September 22 the stock rating was maintained by RBC Capital Markets with “Hold”. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Hold” rating given on Friday, August 11 by RBC Capital Markets. As per Wednesday, February 15, the company rating was upgraded by Needham. The firm earned “Hold” rating on Thursday, April 28 by Needham. The rating was initiated by Bank of America on Friday, July 24 with “Buy”. The rating was maintained by Canaccord Genuity on Monday, September 25 with “Buy”.

Investors sentiment increased to 1.38 in 2017 Q2. Its up 0.28, from 1.1 in 2017Q1. It is positive, as 41 investors sold HOLX shares while 136 reduced holdings. 66 funds opened positions while 179 raised stakes. 267.53 million shares or 3.16% more from 259.34 million shares in 2017Q1 were reported. Meeder Asset reported 1,262 shares. Quantitative Invest Lc owns 269,800 shares. 209,578 were reported by Royal Bank & Trust Of Canada. Hancock Holdg accumulated 27,379 shares. 100,731 were accumulated by Greenleaf Tru. Omers Administration Corp reported 0.03% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Smith Asset Mngmt Grp LP has invested 0.95% in Hologic, Inc. (NASDAQ:HOLX). Maverick Cap Ltd reported 0.05% in Hologic, Inc. (NASDAQ:HOLX). Kames Public Ltd Company reported 0% in Hologic, Inc. (NASDAQ:HOLX). Fil Limited has invested 0.01% in Hologic, Inc. (NASDAQ:HOLX). Cipher Lp reported 74,527 shares. Eastern National Bank & Trust holds 0.65% in Hologic, Inc. (NASDAQ:HOLX) or 195,695 shares. Sta Wealth Management Limited Co holds 10,953 shares or 0.21% of its portfolio. Neuberger Berman Group Limited Liability Com invested in 0.02% or 393,503 shares. 1.69M were reported by Healthcor Mngmt Limited Partnership.

Since April 28, 2017, it had 0 buys, and 10 insider sales for $4.57 million activity. Levy Lawrence M sold $131,838 worth of stock or 2,960 shares. Valenti Peter J. III sold 10,005 shares worth $434,635. $399,317 worth of Hologic, Inc. (NASDAQ:HOLX) shares were sold by ULLIAN ELAINE. Another trade for 25,094 shares valued at $1.13M was sold by CRAWFORD SALLY.

About 142,897 shares traded. OvaScience Inc (OVAS) has declined 82.79% since October 13, 2016 and is downtrending. It has underperformed by 99.49% the S&P500.

Analysts await OvaScience Inc (NASDAQ:OVAS) to report earnings on November, 2. They expect $-0.43 EPS, up 20.37% or $0.11 from last year’s $-0.54 per share. After $-0.45 actual EPS reported by OvaScience Inc for the previous quarter, Wall Street now forecasts -4.44% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com